| Catalog No. | DB927018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 112.17 ng/mL |
|---|
| Range | 156.25 - 10,000 ng/mL |
|---|
| Accession | P16234 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. |
|---|
| Specifications | Olaratumab |
|---|
| Alternate Names | 3G3, IMC-3G3, LY3012207, CAS: 1024603-93-7 |
|---|
| Background | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody developed by Eli Lilly and Company. It selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR). With the trade name Lartruvo, olaratumab has been approved by USA, Canada, and European Union to use in combination with doxorubicin for the treatment of adults with advanced soft-tissue sarcoma (STS) who cannot be cured by cancer surgery or radiation therapy, and who have not been previously treated with doxorubicin. |
|---|
| Note | For Research Use Only. |
|---|
